HIV Viral Load Response to Antiretroviral Therapy According to the Baseline CD4 Cell Count and Viral Load
Authors:
- Andrew N. PhillipsAPAndrew N. Phillips
- Schlomo StaszewskiSSSchlomo Staszewski
- Rainer WeberRWRainer Weber
- Ole KirkOKOle Kirk
- Patrick FrancioliPFPatrick Francioli
- Veronica MillerVMVeronica Miller
- Pietro VernazzaPVPietro Vernazza
- Jens D. LundgrenJLJens D. Lundgren
- Bruno LedergerberBLBruno Ledergerber
Open Access
- 28 November 2001
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 286 (20) , 2560-2567
Abstract
For many patients with chronic, asymptomatic, human immunodeficiency virus (HIV) infection who have not received antiretroviral therapy (ART), it is unclear whether such therapy should be initiated immediately or deferred until the CD4 cell count is lower, and/or the plasma viral load is higher. Viral load levels tend to change only moderately over time in untreated individuals, with at most approximately a 0.1 log copies/mL increase per year, although this rate of increase varies across individuals.1-4 In untreated HIV infection, the risk of acquired immunodeficiency syndrome (AIDS) diseases is known to be small before the CD4 cell count has reached 200 × 106/L5,6 or the viral load has reached 10 000 copies/mL.4 Early therapy brings immediate intervention against a virus known to be causing immune damage, provides the potential for preservation of HIV-specific CD4 cells and the microarchitecture of lymphoid organs, and lowers the viral load to reduce infectivity and prevent AIDS diseases with high case-fatality rates, such as lymphoma, which can occasionally occur at high CD4 cell counts and are refractory to therapy. Delaying therapy, on the other hand, means avoiding the risk of drug toxic effects, selection for drug resistance, and the inconvenience of adhering to a complex regimen for an extended period. It also may mean that when therapy is finally initiated, it is with a more potent and/or more tolerable regimen developed in the intervening period. Furthermore, relatively complete immune reconstitution can be achieved with virologically suppressive therapy, even when initiated in people with very low CD4 counts.7-9 There is no direct evidence from trials of when the optimum time is to initiate therapy in the highly active ART era. The lack of firm data on this issue is illustrated by the differences between various expert recommendations.10-12Keywords
This publication has 23 references indexed in Scilit:
- AIDS across Europe, 1994–98: the EuroSIDA studyThe Lancet, 2000
- Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infectionAIDS, 2000
- Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapyAIDS, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Virological response to protease inhibitor therapy in an HIV clinic cohortAIDS, 1999
- Risk of new AIDS diseases in people on triple therapyThe Lancet, 1999
- Longitudinal HIV-1 RNA Levels in a Cohort of Homosexual MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Regional Differences in Use of Antiretroviral Agents and Primary Prophylaxis in 3122 European HIV-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristicsInternational Journal of Public Health, 1994
- Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndromeThe American Journal of Medicine, 1985